WO2015131978A1 - Robust antibody purification - Google Patents
Robust antibody purification Download PDFInfo
- Publication number
- WO2015131978A1 WO2015131978A1 PCT/EP2015/000361 EP2015000361W WO2015131978A1 WO 2015131978 A1 WO2015131978 A1 WO 2015131978A1 EP 2015000361 W EP2015000361 W EP 2015000361W WO 2015131978 A1 WO2015131978 A1 WO 2015131978A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- range
- hydrophobic
- divinylbenzene
- separation
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/32—Bonded phase chromatography
- B01D15/325—Reversed phase
- B01D15/327—Reversed phase with hydrophobic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
Definitions
- the present invention refers to a method for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies.
- Protein A is initially a 56 kDa surface protein originally found in the cell wall of the bacterium Staphylococcus aureus. It is encoded by the spa gene and its regulation is controlled by DNA topology, cellular osmolarity, and a two-component system called ArlS-ArlR. It has found use in biochemical research because of its ability to bind immunoglobulins. It is originally composed of five homologous Ig-binding domains that fold into a three-helix bundle. Each domain is able to bind proteins from many mammalian species, most notably IgGs.
- mAbs therapeutic monoclonal antibodies
- Production of these drug antibodies typically starts in a bioreactor that contains a suspension of Chinese Hamster Ovary (CHO) cells which secrete the antibody into the extracellular fluid.
- CHO Chinese Hamster Ovary
- the resulting antibodies are then subjected to a series of processes including clarification, filtration, and purification that removes cells, cell debris, host cell proteins (HCP), lipids, DNA, viruses, bacteria, antibody aggregates, etc.
- HCP host cell proteins
- DSP downstream process
- DSP includes one or two bind-elute chromatography purification steps followed by one or two flow-through polishing steps.
- Typical downstream purification processes employ packed columns filled with porous bead-based chromatography media or
- polishing media One of the primary objectives of the polishing media is to reduce the concentration of impurities (e.g. HCP down to ⁇ 10 ppm in reference to mAb concentration).
- a typical antibody purification process includes an initial Protein A affinity capture step followed by one or more ion exchange polishing steps, the purpose of which is to reduce the level of one or more critical impurities such as, e. g. , host cell protein (HCP), antibody
- HCP host cell protein
- Antibody fragments are especially hard to separate from antibodies since they have similar properties, especially FC containing fragments. The latter are generally not separated using Protein A chromatography.
- the problem to be solved is the need for robust and reliable antibody purification step, effectively applicable in a wide range of conditions in a flow through mode, where the level of critical impurities, such as HCP and antibody fragments is reduced.
- the present invention relates to a method for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies, wherein a solution containing antibodies is contacted with a hydrophobic chromatography material for a suitable time period whereby the antibodies stay
- the hydrophobic chromatography material is particulate and it is made of cross-linked vinylbenzene, ethylstyrtene,
- poly(ethyl)styrene-divinylbenzene, or of poIy(ethyl)styrene-divinylbenzene ethyleneglycol-dimethylacrylate resin Preferably the resin is composed of cross-linked polymer composed of styrene and divinylbenzene in a ratio 98 : 2 up to 10 : 90 % by weight.
- the particulate material consists of polystyrene, which is cross-linked with copolymer of
- an aqueous clarified cell culture solution having a pH value in the range of 2 - 11 , preferably in a range of 5 - 9 and a conductivity in the range of 1 - 50 mS/cm, preferably in the range of 2 - 50 mS/cm, is contacte with a hydrophobic chromatography material.
- the aqueous solution is passed through at a flow rate in the range of 150 - 1000 cm/min, preferably in the range of 300 - 900 cm/min.
- the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances is processed after the Protein A affinity binding step. If required, the
- purification sequence includes a treatment with ion exchange resin.
- the separation is processed using particulate, hydrophobic chromatographic separation materials having mean particle diameters in the range of 10 pm to 600 pm, preferably in the range of 20 pm to 150 pm, most preferably in the range of 20 pm to 63 pm.
- Suitable hydrophobic porous polymer beads of this size have preferable pore sizes in the range of 4 - 500 nm, more preferable in the range of 10 - 30 nm, most preferred in the range of 13 nm to 25 nm.
- the purification sequence may include at least one treatment with an ion exchange resin, which preferably is specific for the separation of Protein A.
- an ion exchange resin which preferably is specific for the separation of Protein A.
- the hydrophobic polymer particles consist of cross-linked vinylbenzene, poly(ethyl)styrene-divinylbenzene, or of poly(ethyl)styrene-divinylbenzene ethyleneglycol-dimethylacrylate resin.
- the object of the present invention is, in particular, the use of hydrophobic chromatographic separation materials having pore sizes in the range of 4 nm to 500 nm, preferably in the range of 10 nm - 30 nm, most preferably in the range of 13 nm to 25 nm for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies.
- HCPs host cell proteins
- chromatographic separation materials of the present invention are preferably made of cross-linked vinylbenzene, crosslinked ethylstyrene, polystyrene/polyethylstyrene-divinylbenzene, or of
- the used hydrophobic, rigid polymer beads described herein have mean particle diameters in the range of 10pm to 600 pm, preferably in the range of 20 pm to 150 pm, most preferably in the range of 20 pm to 63 pm, and pore sizes in the range of 4 nm to 500 nm, preferably in the range of 10 nm— 30 nm, most preferably in the range of 13 nm to 25 nm.
- porous hydrophobic interaction materials such as porous poly(di)vinyl aromatic beads are useful for large scale antibody purification from cell culture solutions. These purification steps can be done either upstream or downstream of a capture chromatography step in order to reduce the level of one or more impurities present in a sample (e. g., a clarified cell culture solution) containing a protein of interest.
- a sample e. g., a clarified cell culture solution
- the clarified cell culture solution is brought into contact with the hydrophobic interaction material, for example into contact with porous hydrophobic polystyrene beads, and incubated for a certain period of time in order to selectively reduce the level of low molecular weight substances.
- Said hydrophobic interaction material is especially suitable to be subjected to post Protein A capture antibody solutions and for selectively reducing the level of low molecular weight substances (e. g. antibody fragments, HCPs) by contacting a clarified cell culture solution with the material for a suitable period of time.
- the hydrophobic interaction material e.
- polystyrene beads g., polystyrene beads
- chromatography column(s) or other devices such as filter housings and the like.
- These packed columns are then used for protein purification processes in a flow- through mode, whereby low molecular weight substances, such as antibody fragments and HCPs of the culture solution interact with the hydrophobic, porous interaction material during the flow through the column and the level of low molecular weight substances (e. g. antibody
- the conductivity of the solution is in the range of 1 mS/cm - 50 mS/cm, and especially in the range between 2 - 50 mS/cm.
- this material may mainly consists of polystyrene or polyethylstyrene and can be crosslinked by a mixture of hydrophobic and hydrophilic monomers, for example divinylbenzene (DVB) and ethylene glycol dimethacrylate (EGDMA).
- DVB divinylbenzene
- EGDMA ethylene glycol dimethacrylate
- the porous polymer beads are typically produced by suspension polymerization. They may be produced in a process, which is for example similar to that disclosed in US 4,382,124 and where porosity is introduced into the copolymer beads by suspension polymerization in the presence of a porogen (also known as "phase extender” or precipitant"), which is a solvent for the monomer but a nonsolvent for the polymer.
- a porogen also known as "phase extender” or precipitant
- Conventional porous polymers, such as those prepared according to US 4,382,124 typically encompass the use of a wide range of porogen types, porogen concentrations relative to the monomer phase, monomer types,
- crosslinking monomer types crosslinker levels
- polymerization initiators polymerization initiators and initiator concentrations.
- the present invention is based on the unexpected finding that when the ratio of hydrophobic monomers is in a special range, these polymer beads are especially suitable and effective in purification of antibodies from cell culture liquids.
- the increased capacity for target molecules is primarily achieved when the polymer matrix is altered by increasing the contained shares of hydrophobic molecules in the polymer. This alteration was done considering the balance of the polymer building monomers and of the amount of porogens and of crosslinker levels which altogether influence the parameters of porosity, rigidity and binding capacity of target molecules.
- polymer beads according to the present invention have increased rigidity, and at the same time have a high porosity, thereby providing a high capacity for intraparticle diffusion.
- the hydrophobic porous polymer beads used in the present invention are useful for the removal of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing monoclonal antibodies by contacting the solution with the polymer beads in a liquid chromatography column having a diameter ranging from 1 to 100 cm, preferably in the range of 5 to 50 cm, where the column is operated at pressures up to 100 bar, and preferably at pressure ranging from 0,2 to 80 bar.
- HCPs host cell proteins
- porous polymer beads according to the present invention are typically spherical copolymer beads having an average particle size diameter up to 200 pm, which is the typical size for polymer beads useful for the separation and purification of biomolecules via high performance reverse phase liquid chromatography (such as in columns ranging from 1 to 100 cm in diameter).
- Such hydrophobic separation materials preferably polystyrene beads
- Such hydrophobic separation materials appear to be suitable for the desired separation effect, having pore size in the range of 4 - 500 nm.
- Purification experiments have shown that hydrophobic interaction materials, having average pore sizes between 10- 30 nm, lead to desireable separation results. These desirable separation results can be further improved when spherical hydrophobic polymer beads are used, which are made from a suitable material and an average pore size in the range between 13 - 25 nm.
- Suitable porous polymer beads of the present invention preferably possess surface areas (BET) in the range of 300 to 1000 m 2 /g (square meters per gram), more preferably in the range of 450 to 850 m 2 /g, and most preferably in the range of 500 to 800 m 2 /g.
- BET surface areas
- Suitable monounsaturated vinylaromatic monomers that may be used in the preparation of the porous polymer beads described herein include, but are not limited to styrene, C1 - C4-alkyl-substituted styrenes, vinylnaphthalene and vinylanthracene.
- the monounsaturated vinylaromatic monomer is selected from one or more of styrene and C1 - C4-alkyl-substituted styrenes. Included in the group of suitable C1-C4- alkylsubstituted styrenes are ethylvinylbenzenes, vinyltoluenes,
- porous polymer beads suitable in the present invention particularly may be prepared using one or more monomer(s) selected from the group consisting of vinylbenzene (styrene), ethylstyrene, divinylbenzene, trivinylbenzene, divinyltoluene, divinylnaphthalene, divinylanthracene, divinylxylene and any structural isomer of these monomers.
- vinylbenzene styrene
- ethylstyrene divinylbenzene
- divinylbenzene trivinylbenzene
- divinyltoluene divinylnaphthalene
- divinylanthracene divinylanthracene
- divinylxylene any structural isomer of these monomers.
- porous polymers are prepared using copolymers of vinylbenzene (styrene) and divinylbenzene or ethylstyrene and
- the applied crosslinked porous polymer beads comprise styrene/ and divinylbenzene in a weight ratio to one another of from 98 : 2 to 10 : 90 %.
- (meth)acrylic acids and alkyl esters of (meth)acrylic acids may also be used in addition to the vinylaromatic monomer for the preparation of said hydrophobic, porous polymer beads described herein.
- These aliphatic unsaturated monomers may be used as crosslinking agents in the preparation of the desired polymer beads.
- Suitable aliphatic crosslinking monomers are selected from the group consisting of ethyleneglycol diacrylate, ethyleneglycol
- trimethacrylate dieethyleneglycol divinyl ether and trivinylcyclohexane, and which may be used for the preparation of crosslinked hydrophobic porous polymer beads according to the present invention.
- the aliphatic monomers can be used alone or in combination with polyvinylaromatic monomers mentioned above as crosslinking monomers.
- ethyleneglycol dimethacrylate, glycidyl methacrylate, and diethyleneglycol divinyl ether are especially suitable for the preparation of porous beads.
- these aliphatic crosslinking monomers are used in combination with polyvinylaromatic crosslinking monomers.
- the aliphatic monomers typically are comprised in an amount ranging from 0 to 50 % and preferably in an amount ranging from 0 to 30%, based on the total monomer weight used to form the rigid and porous polymer beads.
- porous polymer beads consisting of polystyrene, which is crosslinked with a copolymer of divinylbenzene or a derivative thereof and a monomer selected from the group consisting of ethyleneglycoi dimethacrylate, and diethyleneglycol divinyl ether and wherein the ratio of polystyrene and crosslinking
- copolymer is in a range of 98 : 2 up to 10 : 90 % by weight.
- porous particles consisting of poly(ethyl)styrene are used, which are crosslinked with copolymer of divinylbentzene and ethyleneglycoi methacrylate in a ratio of 98 : 2 up to 14 : 86 % by weight.
- porous beads consisting of polymer of
- monovinylaromatics which is crosslinked with copolymer of divinylbenzene and ethyleneglycoi methacrylate in a ratio of about 10 : 90 to 98 : 2 % by weight are preferred. More preferred are such porous beads wherein the ratio is about 14 : 86 by weight.
- Preferred hydrophobic porous polymers are selected from one or more of vinylbenzene (styrene) copolymer, ethylvinylbenzene (ethylstyrene) copolymer, divinylbenzene copolymer, crosslinked polystyrene- divinylbenzene copolymer, crosslinked polystyrene ethyleneglycol- dimethacrylate , crosslinked polydivinylbenzene ethyleneglycol- dimethacrylate. Most preferred are crosslinked poly(ethyl)styrene- divinylbenzene copolymer and poly(ethyl)styrene crosslinked with
- Porogens useful for preparing the porous polymers include
- hydrophobic porogens such as (C7 - Cio)aromatic hydrocarbons, and (Ce- C12) saturated hydrocarbons and hydrophilic porogens, such as (C 4 - C10) alkanols and polyalkylene glycols.
- suitable porogens can, for example, be selected from the group consisting of toluene, ethylbenzene, ortho-xylene, meta-xylene, para-xylene. It is understood that, any of the various positional isomers of any of the aforementioned hydrocarbons is suitable.
- the aromatic hydrocarbon is toluene or xylene or a mixture of xylenes or a mixture of toluene and xylene.
- saturated hydrocarbons can also be used as porogens. Suitable examples include, but are not limited to are for example hexane, heptanes or isooctane.
- the preferred saturated hydrocarbon in this case of the present invention is isooctane.
- Suitable alkanols include, but are not limited to isobutyl alcohol, tert-amyl alcohol, n-amyl alcohol, isoamyl alcohol, methyl isobutyl carbinol, (4-methyl-2-pentanol), hexanols and octanols.
- a porogen mixture comprises a hydrophilic porogen selected from one or more (Cs-Csjalkanol and a hydrophobic porogen selected from one or more (C7-Cio)aromatic hydrocarbon.
- the porogen is added to the polymerization suspension in excess, usually in a total amount of 100 to 170 %, preferably from 1 15 - 150 and more preferably from 120 to 140 %, based on weight of the monomers.
- the porogens used to prepare the polymers according to the present invention are mixed with a solvent system, which comprises at least a hydrophobic solvent and optionally a less hydrophobic solvent (“hydrophilic" solvent) and which both support the building of porous beads. It is self-explainatory that the less hydrophobic (or
- hydrophilic solvent has at least some limited water solubility, for example, ranging from 0.5 to 5 % whereas the hydrophobic solvent shows a water solubility of 10 to 100 ppm or less.
- the ratio of porogen with low hydrophobicity (i. e., "hydrophilic porogen") to the hydrophobic porogen is in the range of 0.7 : 1 up to 3 : 1 , preferably in the range of 0.8 : 1 up to 2.5 : 1 , most preferably from 0.9 : 1 to 2.4 : 1.
- Polymerization initiators useful in preparing polymers suitable in the present invention are well known to one of ordinary skill in the art and include monomer soluble initiators like peroxides, hydroperoxides, and related initiators. These initiators are commercially available. Also useful are azo initiators such as azodiisobutyronitrile, azodiisobutyramide and the like. Depending on the nature of the initiator the use levels are in ranges of 0.5 to 10 % based on the total weight of the comprising vinyl monomers. [0043] Furthermore, dispersants or suspending agents useful for
- preparing the porous polymer beads may be customary surfactants, which are ionic and may contain hydrophobic alkyl chains containing 1 to 24 carbon atoms.
- Another commercially available group of dispersants which is suitable in the suspension polymerization are nonionic surfactants, which are based on epoxidized hydroxyalkyicellulose derivatives. Typically these additives are used at levels of about 0,01 up to 4 % based on the total weight of the aqueous phase.
- other dispersants may be used and can be applied together with those surfactants and dispersants.
- polymeric dispersants including celluloses, polyvinyl pyrrolidones, polyvinyl alcohols, starches and the like may be used in mixtures with other surfactants or dispersants used herein. But most preferred is the addition of ionic surfactants, which can be easily removed from the prepared polymer beads by rinsing with water.
- the preparation of the polymer beads may include a treatment to cleanse the polymer surface of residues of dispersants and suspending agents used during the polymerization.
- This treatment may include an enzyme treatment as disclosed in the patent literature (JP 61- 14 704 or JP 57-98504 or EP 1 179 732 B1).
- Prepared polymer beads are especially suitable in packed columns, because of their porosity and mechanical strength.
- these porous and rigid polymer beads are useful for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing antibodies by contacting the solution with these polymer beads in liquid chromatography columns even at elevated pressures.
- HCPs host cell proteins
- These beads are especially suitable for high performance separations and purifications of biomolecules at high throughput rates without pressure buildup because of prolonged use.
- Porous polymer beads as used in the present invention are characterized by selected porosities and pore size distributions, which may be determined by inverse size- exclusion chromatography (iSEC).
- the polymer beads suitable in the present invention typically have a porosity ⁇ in the range of 0.4 to 1.0 and preferably in the range of 0. 45 to 0.75.
- These beads possess surface area ranging from 300 to 100 m 2 /g [BET], more preferably from 450 to 850 m 2 /g, and most preferably in the very narrow range of 500 to 800 m 2 /g.
- polymer beads as disclosed here are unexpectedly well suited for the separation of host cell proteins (HCPs), antibody fragments and low molecular weight substances from solutions containing monoclonal antibodies. Because of their chemical nature and their nano porous structure these materials are especially suitable for hydrophobic interaction with low molecular weight proteins and can be incorporated into
- chromatography columns is increased, while the levels of critical impurities, such as HCP and antibody fragments is reduced.
- the applied polystyrene beads need not to be derivatized and, therefore are much more cost effective than commonly used chromatography gels in this purification step.
- the separation materials described herein are fairly inexpensive and can be regenerated, thereby reducing the overall costs of antibody purification platform and beyond.
- hydrophobic materials described herein can be used either upstream or downstream of a capture chromatography step to reduce the level of one or more impurities.
- a sample is contacted with a sample
- the Protein A affinity chromatography step is used before contacting a sample with a hydrophobic material.
- hydrophobic material is not limited to the given examples, since it is based on size exclusion mechanisms and hydrophobic adsorption of low molecular weight substances, especially compounds of molecular mass ⁇ 70kDa. This results in a selective removal of monoclonal antibody related molecules, such as antibody fragments or HCP.
- the present invention provides a chromatography based antibody purification step, wherein the chromatography material described herein can be regenerated and is applicable in wide operation window (e. g. pH 3-11 ; conductivity 1mS/cm-50mS/cm, operational velocity 150cm/min - 1000cm/min).
- wide operation window e. g. pH 3-11 ; conductivity 1mS/cm-50mS/cm, operational velocity 150cm/min - 1000cm/min.
- the resistance of the porous polymer beads at low and high pH values is of great advantage here because a satisfactory regeneration is possible and these materials have a considerably longer life span.
- the removal of low molecular weight substances, especially compounds of molecular mass ⁇ 70kDa, from clarified cell culture broths using the hydrophobic porous polymer beads described herein may be performed both at industrial and as well as micro- scale, as the selected separation materials are stable against pressure and are not prone to deformation at high pressures.
- the user is free in the manner of carrying out the chromatographic purification. It is self- explanatory that depending on the nature of the applied cell culture and of the low molecular weight proteins, one or the other composition of the porous polymer particles may be advantageous for the purification step.
- the expert has the choice between porous polymers made from pure (vinyl) alkyl aromatics or those that are crosslinked by suitable acrylates. In this case, the most suitable polymers beads can be readily indentified by one of ordinary skill in the art.
- these materials are not limited to be used for the removal of low molecular weight substances, especially compounds of molecular mass ⁇ 70kDa like antibody fragments or HCP.
- Protein A which is not separated in previous purification steps or which is washed out, can easily be separated from cell culture media using the porous hydrophobic polymer beads according to the present invention.
- the separation of Protein A from cell culture media can be effected independently from the pH value of the medium using the porous polymer beads.
- PS-DVB- EGDMA resin is able to adsorb Protein A in pH 4.00 and pH 8.00 solutions under static binding conditions.
- alkyl(meth)acrylate refers to either corresponding acrylate or methacrylate ester; similarly, the term “(meth)acrylic” refers to either acrylic or methacrylic acid and the corresponding derivatives, such as esters or amides. As indicated above, all percentages referred to will be expressed in weight percent (%), based on total weight of polymer or composition (solution) involved, unless specified otherwise.
- copolymer refers to polymer compositions containing units of two or more different monomers, including positional isomers.
- microspheres may be established by scanning electron microscopy (SEM) analysis.
- the pore size is determined by methods which are known in the art. Macropores may be determined using mercury porosimetry. In this case experiments for analyzing pore sizes are done following the protocol of the used mercury porosimetry analyzer (e. g. AutoPore IV 9500,
- Microspheres are re-suspended in distilled water and the dispersion is dropped on a piece of aluminum foil and dried at ambient atmosphere.
- the sample is placed on a metal stub with double-sided conductive adhesive tape and is coated with a thin gold film under reduced pressure below 5 Pa with a JFC-1600 fine coater (JEOL, Japan).
- the pore size of mesopores and their specific surface area can also determined using nitrogen adsorption/ desorption measurements (BET-method), which are performed by following standard protocols. This latter method may also be used for determining the BET surface area.
- BET-method nitrogen adsorption/ desorption measurements
- HCPs host cell proteins
- ELISA test system which is used.
- ELISA test systems are process-specific for the detection of HCPs from a specific bacterium or from specific cultured cell lines (e. g. Chinese Hamster Ovary (CHO) cell cultures).
- CHO HCP ELISA kit The principle of, for example, a CHO HCP ELISA kit is based on the binding of CHO proteins in samples to two antibodies, one immobilized on the microwells, and the other conjugated to horseradish peroxidase (HRP). After incubation and a washing step, chromogenic substrate (TMB) is added and color is developed by the enzymatic reaction of HRP on the substrate, which is directly proportional to the amount of antigen present in the sample. Stopping Solution is added to terminate the reaction, and absorbance at 450nm is then measured using an ELISA microwell reader. The concentration of CHO proteins in samples and control is calculated from a standard curve of CHO HCPs.
- HRP horseradish peroxidase
- proteins become unfolded and coated with SDS detergent molecules, acquiring a high net negative charge that is proportional to the length of the polypeptide chain.
- SDS detergent molecules When loaded onto a gel matrix and placed in an electric field, the negatively charged protein molecules migrate towards the positively charged electrode and are separated by a molecular sieving effect.
- the size of a protein After visualization by a protein- specific staining technique, the size of a protein can be estimated by comparison of its migration distance with that of a standard of known molecular weight. It is also possible to blot the separated proteins onto a positively charged membrane and to probe with protein-specific antibodies in a procedure termed western blotting.
- Fig. 1 a mAb03 reduction and HCP reduction (%) in various antibody post
- Fig. 1 b mAb05 reduction and HCP reduction (%) in various antibody post
- porous PS-DVB particulate material having 31 ,4nm diameter average pores.
- Fig. 2b mAb05 reduction and HCP reduction (%) after treatment at
- Fig. 2c mAb05 reduction and HCP reduction (%) after treatment at
- Fig. 3 mAb reduction and HCP reduction (%) after treatment with PS- DVB particulate material having 15,8nm diameter average pores.
- Fig. 4 mAb reduction and HCP reduction (%) after treatment with PS- DVB particulate material having 15,8nm diameter average pores and classified to different particles sizes, ranging from >63pm (top line), to 40-63pm (middle line) and to 20-40pm (bottom line).
- Fig. 5 mAb03 levels and FC containing fragment break through levels at different loadings for PS-DVB (PS01) - average pore size 31 ,4nm, for PS-DVB (PS02) - average pore size 20,4nm and PS- DVB (PS03) - average pore size 15,8nm particulate materials.
- Fig. 6 mAb03 levels and HCP break through levels at different loadings for PS-DVB-EGDMA particulate material, where 30422 (dso- 36, 1 ⁇ ) and PS02 (d50-40,9 m) materials consists of
- poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers, 30410 (d5o-35,2pm) material consists of poly(ethyI)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers and 30423 consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (50%) and ethylene glycol dimethylacrylate (50%) copolymers.
- mAb06 HCP break through levels at different loadings for PS- DVB-EGDMA particulate material, where 30422 (dso-36,1 pm) and PS02 (d5o-40,9pm) materials consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers, 30410 (dso-35,2pm) material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- Run 3 and Run 5 performed with mAb06 post Protein A pool (pH 5.0, conductivity-1 ,4mS/cm) and run 4, run 7 and run 9 were performed with mAb06 post Protein A pool, where NaCI was added to increase the pool conductivity to 3mS/cm.
- b mAb06 LMW (%) break through levels at different loadings for PS-DVB-EGDMA particulate material, where 30422 (d50-36, pm) and PS02 (d5o-40,9pm) materials consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers, 30410 (dso- 35,2pm) material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- Run 3 and Run 5 performed with mAb06 post Protein A pool (pH 5.0, conductivity-1 ,4mS/cm) and run 4, run 7 and run 9 were performed with mAb06 post Protein A pool, where NaCI was added to increase the pool conductivity to 3mS/cm.c: mAb05 LMW(%) break through levels at different loadings for PS- DVB-EGDMA particulate material, where PS02 (d50-40,9pm) materials consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers, MS39 (d50-35,2pm) material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers and AC is natural activated carbon (Nuchar HD).
- PS02 (d 5 o-40,9pm) materials consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers
- MS39 (d5o-35,2pm) material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers
- AC is natural activated carbon
- Fig. 8 mAb03 HCP break through levels at different loadings for PS-
- DVB-EGDMA particulate material where 30410 material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers. Runs 1-3 represent sequential runs after column cleaning and
- Fig. 9 mAb03 HCP break through levels at different loadings for PS-
- DVB-EGDMA particulate material where 30410 material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- P242 is competitor hydrophobic material
- P248 is competitor hydrophobic material
- Nuchar HD is activated carbon material, which is sized to 40-63pm.
- Fig. 10a HCP levels in various mAb03 post Protein A
- PS-DVB-EGDMA particulate material e. g. Prosep Ultra Plus (PUP), Mab Select Sure, Eshmuno A
- PS-DVB-EGDMA particulate material e. g. Prosep Ultra Plus (PUP), Mab Select Sure, Eshmuno A
- this material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethacrylate (30%) copolymers.
- Fig. 10b HCP levels in various mAb07 Protein A (e.g. PUP, MAB Select
- Fig. 1 mAb03 HCP break through levels at different loadings for PS- DVB-EGDMA particulate material, where in one experiment NaCI was added to 0,5M concentration.
- 30451 materials consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers
- 30410 material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- Fig. 1 mAb03 HCP break through levels at different loadings for PS- DVB-EGDMA particulate material, where in one experiment NaCI was added to 0,5M concentration.
- 30451 materials consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers
- 30410 material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and
- 30410 material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- P242 is competitor hydrophobic material
- P248 is competitor hydrophobic material as well.
- Fig. 13 Reduced SDS PAGE analysis of Protein A adsorption on DVB- EGDMA, Eshmuno® S, and Eshmuno® Q resins
- the organic phase is added to the water phase in a reactor vessel and the two phases are emulsified at 25°C with a stirrer at 480 rpm to achieve the anticipated particle size distribution. After 60 min 640 g water are added and the reaction mixture is heated up to 72°C. For two hours the temperature is kept at 72°C and then increased to 82°C. The mixture is polymerized at 82°C for additional two hours.
- the suspension is filtered on a filter funnel and the particles are washed with 1.5 liter water of 60°C, followed by 5 liter methanol at 60°C, 5 liter of toluene and 2 liter of methanol at 40°C.
- the final product is dried in a vacuum oven for 24 hours at 50°C and 50 mbar. The yield regarding dry mass is quantitative. Depending from the anticipated particle size
- a) particulate material consisting of polyethyl)styrene (m), crosslinked with divinylbenzene copolymers (PS-DVB)
- particulate material consisting of polystyrene (m), crosslinked with divinylbenzene copolymers and ethylene glycol dimethylacrylate (PS-DVB- EGDMA) copolymers, are tested for impurity removal in static mode.
- Phosphate buffer saline (PBS, 10 mM phosphate, pH 7.4) is used as an equilibrium and wash buffer for the tested materials prior to subjecting them to a post Protein A capture pools.
- Samples are subjected to two different post Protein A capture pools overnight under vigorous shaking and under a set of loadings corresponding to an antibody loading (weight ratio) per volume of particulate material. Those loadings are 0,5, 1 and 2 kg/L. After overnight incubation the particulate material is filtered out and the samples are analyzed using size exclusion chromatography, HCP ELISA and HPLC Prot A methods to gather the performance data. The result of this experiment shows that both the particulate materials used in this
- the antibody yields in all of those experiments were greater than 80%.
- a) particulate material consisting of poly(ethyI)styrene (m), crosslinked with divinylbenzene copolymers (PS-DVB)
- particulate material consisting of poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers and ethylene glycol dimethylacrylate (PS-DVB- EGDMA) copolymers,
- Phosphate buffer saline PBS, 10 mM phosphate, pH 7.4
- PBS Phosphate buffer saline
- particulate material consisting of
- poly(ethy)styrene (m) crosslinked with divinylbenzene copolymers (PS- DVB), is evaluated for its ability to remove HCP from various antibody post Protein A capture pools, where post Protein A pools are adjusted to a wide range of pH and conductivity conditions. Measurements are made in duplicates, mixing 25 ⁇ particulate material and 1000 ⁇ PPP (p_hosvitin _hosphop_eptides; diluted 1:4 in buffers of different pH and NaCI cone.) and incubated for 30 minutes. HCP reduction is quantified via ELISA assays, whereas mAb reduction is quantified via SDS-PAGE and subsequent band analysis is performed via BioDoc gel analysis software (see Figure 1a-d).
- Figure 1a mAb03 reduction and HCP reduction (%) after treatment at different conditions
- Figure 1b mAb05 reduction and HCP reduction (%) after treatment at different conditions
- Figure 1c mAb07 reduction and HCP reduction (%) after treatment at different conditions
- particulate materials consisting of
- poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers (PS- DVB) having different average pore sizes are evaluated for their ability to remove HCP from clarified cell culture pool, which has been adjusted to a wide range of pH and conductivity conditions. Measurements are made in duplicates, mixing 25 ⁇ particulate material and 1000 ⁇ PPP (diluted 1 :4 in buffers of different pH and NaCI cone.) and incubated for 30 minutes.
- HCP reduction is quantified via ELISA assays, whereas mAb reduction is quantified via SDS-PAGE and subsequent band analysis is performed via BioDoc gel analysis software (see Figure 2a-c):
- Figure 2a mAb05 reduction and HCP reduction (%) after treatment at different conditions with PS-DVB particulate material having an average pore size of 31 ,4nm in diameter.
- Figure 2b mAb05 reduction and HCP reduction (%) after treatment at different conditions with PS-DVB particulate material having an average pore size of 20,4nm in diameter.
- Figure 2c mAb05 reduction and HCP reduction (%) after treatment at different conditions with PS-DVB particulate material having an average pore size of 15,8nm in diameter
- poly(ethyl)styrene (m), crosslinked with divinylbenzene copolymers (PS- DVB) having an average pore size of 5,8nm (estimated by inverse SEC and PSS software) is evaluated for its ability to remove HCP from clarified cell culture pool. Measurements are made in duplicates, mixing 25 ⁇ particulate material and 1000 ⁇ PPP (diluted 1 :4 in 50 mM TRIS pH 9 0.5 M NaCI) and incubated for 30 minutes. HCP reduction is quantified via ELISA assays, whereas mAb reduction is quantified via SDS-PAGE and subsequent - band analysis is performed via BioDoc gel analysis software (see Figure 3):
- Figure 3 mAb reduction and HCP reduction (%) after treatment with PS- DVB particulate material having average pore sizes of 15,8nm in diameter.
- particulate material consisting of
- Figure 4 mAb reduction and HCP reduction (%) after treatment with PS- DVB particulate material having 15,8nm diameter average pores and classified to different particles sizes, ranging from >63pm (top line), to 40- 63pm (middle line) and to 20-40pm (bottom line).
- particulate materials consisting of
- poly(ethyl)styrene (m) crosslinked with divinylbenzene copolymers (PS- DVB) having different average pore size are evaluated for their ability to remove introduced heavy chain (FC) containing antibody fragments after papain digestion and Prot A affinity purification from a post Protein A antibody pool, where the known amount of digested and purified FC containing antibody fragments is spiked in antibody post Protein A pool.
- FC introduced heavy chain
- Measurements are performed in dynamic mode, of packing the particulate material in the chromatographic column and charging it with prepared feed at 300cm/h after equilibration using 50mM acetate buffer at pH 5.0. Fragment levels are quantified via SEC-HPLC (see Figure 5):
- Figure 5 mAb03 levels and FC containing fragment break through levels at different loadings for PS-DVB (PS01) - average pore size 31 ,4nm, for PS-DVB (PS02) - average pore size 20,4nm and PS-DVB (PS03) - average pore size 15,8nm particulate materials.
- particulate materials consisting of
- poly(ethyl)styrene (m) crosslinked with divinylbenzene (PS-DVB) and ethylene glycol dimethylacrylate (PS-DVB-EGDMA) copolymers in various ratios are evaluated for their ability to remove HCP from a post Protein A antibody pool. Measurements are performed in dynamic mode, of packing the particulate material in the chromatographic column and charging it with mAb03 post Protein A feed (pH 5.0 LF ⁇ 3mS/cm) @ 350cm/h after equilibration with 50mM Acetate buffer pH 5.0, LF ⁇ 2mS/cm for at >20CV. The starting HCP concentration is 900 ng/ml and mAb concentration 8,4mg/ml. All materials sized to 20-40pm particle size and average particle size distribution estimated with Accusizer. Antibody levels were quantified via SEC-HPLC arid HCP amount via ELISA measurements (see Figure 6):
- Figure 6 mAb03 levels and HCP break through levels at different loadings for PS-DVB-EGDMA particulate material, where 30422 (d50-36, pm) and PS02 materials consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene copolymers, 30410 (d50-35,2pm) material consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers and 30423 (d50-35,5pm) consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene (50%) and ethylene glycol dimethylacrylate (50%) copolymers.
- Example 9 Example 9
- particulate materials consisting of
- poly(ethyl)styrene (m) crosslinked with divinylbenzene (PS-DVB) and ethylene glycol dimethylacrylate (PS-DVB-EGDMA) copolymers in various ratios are evaluated for their ability to remove HCP and low molecular weight substances (e. g. antibody fragments) from various post Protein A antibody pools. Measurements are performed in dynamic mode, of packing the particulate material in the chromatographic column and charging it with antibody post Protein A feed (pH 5.0) @ 300cm/h after equilibration with 50mM Acetate buffer pH 5.0, LF ⁇ 2mS/cm for at >20CV. All materials sized to 20-40 m particle size and average particle size distribution estimated with Accusizer.
- Antibody levels are quantified via SEC-HPLC and HCP amount via ELISA measurements (see Figure 7a-d):
- Run 3 and Run 5 are performed with mAb06 post Protein A pool (pH 5.0, conductivity-1 ,4mS/cm) and run 4, run 7 and run 9 are performed with mAb06 post Protein A pool, where NaCI is added to increase the pool conductivity to 3mS/cm.
- Figure 7b mAb06 LMW(%) break through levels at different loadings for PS-DVB-EGDMA particulate material, where 30422 (d50-36,1pm) and PS02 (d5o-40,9pm) materials consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene copolymers, 30410 (dso-35,2 m) material consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- Run 3 and Run 5 performed with mAb06 post Protein A pool (pH 5.0, conductivity- 1 ,4mS/cm) and run 4, run 7 and run 9 are performed with mAb06 post Protein A pool, where NaCI is added to increase the pool conductivity to 3mS/cm.
- Figure 7c mAb05 LMW(%) break through levels at different loadings for PS-DVB-EGDMA particulate material, where PS02 (d50-40,9pm) materials consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene
- MS39 (d50-35,2pm) material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers and AC is natural activated carbon (Nuchar HD).
- FIG. 7d mAb05 HCP break through levels at different loadings for PS- DVB-EGDMA particulate material, where PS02 (dso-40,9 m) materials consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene
- MS39 (dso-35,2pm) material consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers and AC is natural activated carbon (Nuchar HD).
- poly(ethyl)styrene (m) crosslinked with divinylbenzene (PS-DVB) (70%) and ethylene glycol dimethylacrylate (PS-DVB-EGDMA) (30%) copolymers are evaluated for their ability to remove HCP from various post Protein A antibody pools and reuse the particulate material after cleaning.
- Measurements are performed in dynamic mode, of packing the particulate material in the chromatographic column and charging it with post Protein A antibody feed (pH 5.0) @ 300cm/h after equilibration with 50mM Acetate buffer pH 5.0, LF ⁇ 2mS/cm for at >20CV.
- the materials sized to 40-63pm particle size and average particle size distribution estimated with Accusizer After use, the column is eluted with 60% DPG solution for 20CV and re- equilibrated with 50mM Acetate buffer pH 5.0, LF ⁇ 2mS/cm for at >20CV.
- Antibody levels are quantified via SEC-HPLC and HCP amount via ELISA measurements (see Figure 8):
- Figure 8 mAb03 HCP break through levels at different loadings for PS- DVB-EGDMA particulate material, where 30410 material consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers. Run 1-3 represent sequential runs after column cleaning and reequilibration.
- Example 11
- particulate material consisting of
- Figure 9 mAb03 HCP break through levels at different loadings for PS- DVB-EGDMA particulate material, where 30410 material consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- 30410 material consists of poly(ethyl)styrene (m) crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- P242 is competitor hydrophobic material
- P248 is competitor hydrophobic material
- Nuchar HD is activated carbon material, which was sized to 40-63pm.
- This representative example demonstrates that monoclonal antibody fragments can be selectively removed from a solution of a monoclonal antibody by static treatment with different types of activated carbon and different type of hydrophobic resins.
- Solutions of AB08 are prepared with approximately 1.7% of monoclonal antibody fragments and then are treated with one of three different types of activated carbon or two different types hydrophobic resin under static conditions, as described below.
- MAB08 stock solutions are prepared by treatment of the purified monoclonal antibody with papain enzyme to digest them into fragments. After digestion the enzyme is inactivated by adding a solution of 0.3 M iodoacetate.
- the digested monoclonal antibody solutions are dialyzed into water with dialysis tubing (Standard RC Dialysis Trial Kits, Spectra/Por 1-3, 3.5K MWCO, 54 mm FLAT WIDTH, serial number: 132725, Spect rum Laboratories, Inc., Collinso Dominguez, CA, 90220 USA) to remove buffer salts.
- the dialysis tubing contains approximately 0.15 L of the digested monoclonal antibody solutions is submerged in 4.0 L of water for 24 hours. The dialysis tubing is then moved into a new container containing 4.0 L of fresh water where it remained submerged for an additional 24 hours.
- a MAB08 solution spiked with monoclonal antibody fragments is prepared from 18.0 mL of digested MAB II, 72.0 mL of undigested MAB08 in water, and 9.0 mL of 250 mM Tris at pH 7. The solution is then filtered through a 0.22 prn membrane (Stericup ® -GP with a 0.22 pm Millipore Express ® PLUS membrane, 250 mL, catalogue number: SCGPU02RE, EMD Millipore Corp. Bilferica, MA, 01821 , USA).
- MAB04 is produced by a CHO cell culture, and subjected to a Protein A chromatography capture process eluting the product with 50 mM acetate at pH 3.5.
- the solution pH is adjusted to pH 7.5 using 1.8 M Tris base and then filtered through a 0.22 pm membrane (Stericup ® -GP with a 0.22 pm Millipore Express ® PLUS membrane, 250 mL, catalogue number: SCGPU02RE, EMD Millipore Corp. Billerica, MA, 01821 , USA).
- the resulting solution is determined by size exclusion chromatography to have 1.99% of fragments determined by an ELISA HCP assay to have 21 ppm of HCP.
- the percentage of fragments remaining in the samples is determined by size exclusion chromatography.
- the HCP concentration remaining in the samples is determined by an ELISA assay.
- Table 5a Recovery of monoclonal antibody and percentage of fragments after static treatment of MAB04 solution with a DVB-EGDMA hydrophobic resin.
- Table 5b Recovery of monoclonal antibody and percentage of fragments after static treatment of MAB04 solution with a cross-linked cross-linked DVB hydrophobic resin.
- Solutions of MAB05 are prepared with approximately 0.31 % of monoclonal antibody fragments and 578 ppm of HCP. This solution is then treated with one of two different hydrophobic resins under static conditions, as described below.
- MAB05 is produced by a CHO cell culture, and subjected to a Protein A chromatography capture process eluting the product with 50 mM acetate at pH 3.5.
- the solution pH is adjusted to pH 7.5 using 1.8 M Tris base and then filtered through a 0.22 pm membrane (Stericup ® -GP with a 0.22 pm Millipore Express ® PLUS membrane, 250 mL, catalogue number: SCGPU02RE, EMD Millipore Corp. Billerica, MA, 01821 , USA).
- the resulting solution is determined by size exclusion chromatography to have 0.31% of fragments and determined by an ELISA HCP assay to have 578 ppm of HCP.
- hydrophobic resins The experiment demonstrates that static treatment of a monoclonal antibody solution with hydrophobic resins selectively removes monoclonal antibody fragments and HCP. As the amount of hydrophobic resin added to the monoclonal antibody solution is increased, the
- hydrophobic resins can be used to selectively remove monoclonal antibody fragments and HCP from a solution of a monoclonal antibody under static binding conditions.
- Table 6a Recovery of monoclonal antibody and percentage of fragments after static treatment of MAB04 solution with a DVB-EGDMA hydrophobic resin.
- particulate material consisting of
- poly(ethyl)styrene (m), crosslinked with divinylbenzene (PS-DVB) (70%) and ethylene glycol dimethylacrylate (PS-DVB-EGDMA) (30%) copolymers was evaluated for its ability to remove HCP from various antibody post Protein A pools.
- the post Prot A pools are generated using commercially available Prosep ® Ultra Plus or Mab Select Sure ® or Eshmuno ® A
- Measurements are performed in dynamic mode, of packing the particulate material in the chromatographic column and charging it with antibody post Protein A feed (pH 5.0) @ 600cm/h after equilibration with 50mM Acetate buffer pH 5.0, LF ⁇ 2mS/cm for at >20CV.
- Antibody levels were quantified via SEC-HPLC an d HCP amount via ELISA measurements (see Figure 10):
- FIG. 10a HCP levels in various mAb03 post Protein A
- PS-DVB-EGDMA particulate material e. g. Prosep ® Ultra Plus (PUP), Mab Select Sure ® , Eshmuno ® A
- PS-DVB-EGDMA particulate material e. g. Prosep ® Ultra Plus (PUP), Mab Select Sure ® , Eshmuno ® A
- this material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- PS-DVB-EGDMA particulate material e. g. Prosep ® Ultra Plus (PUP), Mab Select Sure ® , Eshmuno ® A
- PS-DVB-EGDMA particulate material e. g. Prosep ® Ultra Plus (PUP), Mab Select Sure ® , Eshmuno ® A
- particulate material consisting of poly(ethyl)styrene (m), crosslinked with divinylbenzene (PS-DVB) (70%) and ethylene glycol dimethylacrylate (PS-DVB-EGDMA) (30%) copolymers is evaluated for their ability to remove HCP from salt containing post Protein A antibody pools. Measurements are performed in dynamic mode, of packing the particulate material in the chromatographic column and charging it with salt containing (e.g. 0.5m NaCI) antibody post Protein A feed (pH 5.0) @ 600cm/h after equilibration with 50mM Acetate buffer pH 5.0, LF ⁇ 2mS/cm for at >20CV. Antibody levels are quantified via SEC- HPLC and HCP amount via Elisa measurements (see Figure 11):
- Figure 11 mAb03 HCP break through levels at different loadings for PS- DVB EGDMA particulate material, where in one experiment NaCL was added to 0.5M concentration.
- 30451 material consists of polystyrene (m), crosslinked with divinylbenzene copolymers
- 30410 material consists of polystyrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- particulate material consisting of
- poly(ethyl)styrene (m), crosslinked with divinylbenzene (PS-DVB) (70%) and ethylene glycol dimethylacrylate (PS-DVB-EGDMA) (30%) copolymers is evaluated in comparison to commercially available hydrophobic material for their ability to remove HCP from various antibody post Protein A pools. Measurements are performed in dynamic mode, of packing the particulate material in the chromatographic column and charging it with post Protein A antibody feed (pH 5.0) @ 900cm/h after equilibration with 50mM Acetate buffer pH 5.0, LF ⁇ 2mS/cm for at >20CV.
- Antibody levels are quantified via SEC-HPLC and HCP amount via ELISA measurements (see Figure 12): Figure 12: rr»Ab03 HCP break through levels at different loadings for PS- DVB-EGDMA particulate material, where 30410 material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- 30410 material consists of poly(ethyl)styrene (m), crosslinked with divinylbenzene (70%) and ethylene glycol dimethylacrylate (30%) copolymers.
- P242 is competitor hydrophobic material
- P248 is competitor hydrophobic material.
- the prepared solutions are then filtered through a 0.22 pm membrane (Stericup ® -GP with a 0.22 pm Millipore Express ® PLUS membrane, 250 ml_, catalogue number: SCGPU02RE, EMD Millipore Corp. Billerica, MA, 01821 , USA) and then are treated with one of three different types of resins (e.g. DVB-EGDMA resin, Eshmuno® S, Eshmuno® Q) under static conditions, as described below.
- DVB-EGDMA resin Eshmuno® S, Eshmuno® Q
- Table 7 Protein A levels after static treatment with three different resin types at two different pH conditions.
- Figure 13 Reduced SDS PAGE analysis of Protein A adsorption on DVB- EGDMA, Eshmuno® S, and Eshmuno® Q resins according to Example 18 with
- particulate material consisting of
- poly(ethyl)styrene (m), crosslinked with divinylbenzene (PS-DVB) (70%) and ethylene glycol dimethylacrylate (PS-DVB-EGDMA) (30%) copolymers (686,75m 2 /g surface area, 14 nm average pore size, and 41 ⁇ average particle size) is evaluated for its ability to remove HCP from post Protein A antibody pools.
- the post Prot A pools are generated using commercially available Prosep ® Ultra Plus, where clarified cell culture containing antibody of interest is loaded on re-equilibrated Prot A column to 40mg/ml binding capacity values @ 600cm/h and then washed with re-equilibration buffer for 5 CV following the 5CV elution using 50mM Glycyne and 50mM Acetic acid buffer at pH 3.5.
- the collected pools are then charged to the particulate material consisting of poly(ethyl)styrene (m), crosslinked with divinylbenzene (PS-DVB) (70%) and ethylene glycol dimethylacrylate (PS- DVB-EGDMA) (30%) copolymers, Eshmuno ® CPX, Eshmuno ® Q individually and in combination, directly connecting all devices.
- m poly(ethyl)styrene
- PS-DVB crosslinked with divinylbenzene
- PS- DVB-EGDMA ethylene glycol dimethylacrylate
- Measurements are performed in dynamic mode, of packing the particulate material in the chromatographic column and charging it with antibody post Protein A feed (pH 6.75, conductivity ⁇ 2,7mS/cm, ⁇ 000ng/ml HCP amount) @ 600cm/h after equilibration with 20mM Phosphate buffer pH 6.75, LF ⁇ 4mS/cm for at >20CV.
- antibody post Protein A feed pH 6.75, conductivity ⁇ 2,7mS/cm, ⁇ 000ng/ml HCP amount
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Peptides Or Proteins (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15706374.4A EP3114455B1 (en) | 2014-03-04 | 2015-02-18 | Robust antibody purification |
| SG11201607341SA SG11201607341SA (en) | 2014-03-04 | 2015-02-18 | Robust antibody purification |
| ES15706374T ES2784638T3 (en) | 2014-03-04 | 2015-02-18 | Robust antibody purification |
| JP2016555750A JP7037275B2 (en) | 2014-03-04 | 2015-02-18 | Robust antibody purification |
| US15/123,110 US10457720B2 (en) | 2014-03-04 | 2015-02-18 | Robust antibody purification |
| CN201580011575.6A CN106103477B (en) | 2014-03-04 | 2015-02-18 | Robust Antibody Purification |
| DK15706374.4T DK3114455T3 (en) | 2014-03-04 | 2015-02-18 | ROBUST ANTIBODY CLEANING |
| KR1020167027436A KR102405382B1 (en) | 2014-03-04 | 2015-02-18 | Robust antibody purification |
| CA2942134A CA2942134C (en) | 2014-03-04 | 2015-02-18 | Robust antibody purification |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947761P | 2014-03-04 | 2014-03-04 | |
| US61/947,761 | 2014-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015131978A1 true WO2015131978A1 (en) | 2015-09-11 |
Family
ID=52589333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2015/000361 Ceased WO2015131978A1 (en) | 2014-03-04 | 2015-02-18 | Robust antibody purification |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10457720B2 (en) |
| EP (1) | EP3114455B1 (en) |
| JP (2) | JP7037275B2 (en) |
| KR (1) | KR102405382B1 (en) |
| CN (1) | CN106103477B (en) |
| CA (1) | CA2942134C (en) |
| DK (1) | DK3114455T3 (en) |
| ES (1) | ES2784638T3 (en) |
| SG (2) | SG11201607341SA (en) |
| WO (1) | WO2015131978A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016096071A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Patent Gmbh | Target molecule capture from crude solutions |
| CN109715648A (en) * | 2016-09-15 | 2019-05-03 | 克拉维格两合股份有限公司 | Polymeric mesh object is used for the purposes of macromolecule purifying |
| US11186858B1 (en) | 2016-03-15 | 2021-11-30 | Fresenius Kabi Deutschland Gmbh | Methods for increasing biosimilarity |
| WO2023007445A1 (en) * | 2021-07-29 | 2023-02-02 | Csl Behring Ag | Method of purifying immunoglobulin g and uses thereof |
| US12139526B2 (en) | 2015-12-03 | 2024-11-12 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106674403A (en) * | 2017-01-03 | 2017-05-17 | 宏葵生物(中国)有限公司 | Preparation method of polystyrene microspheres for enhancing immunoturbidimetry and application thereof |
| US12429465B2 (en) | 2018-02-20 | 2025-09-30 | Korea University Research And Business Foundation | Multi-column for isolating exosomes and exosome isolation method |
| JP7404689B2 (en) * | 2018-08-06 | 2023-12-26 | 東ソー株式会社 | Antibody adsorbent with immobilized Fc-binding protein and antibody separation method using the same |
| JPWO2022260091A1 (en) * | 2021-06-10 | 2022-12-15 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5798504A (en) | 1980-12-11 | 1982-06-18 | Mitsubishi Monsanto Chem Co | Production of vinyl polymer |
| US4382124A (en) | 1958-07-18 | 1983-05-03 | Rohm And Haas Company | Process for preparing macroreticular resins, copolymers and products of said process |
| JPS61141704A (en) | 1985-11-11 | 1986-06-28 | Mitsubishi Kasei Vinyl Co | Production of vinyl polymer |
| US4686269A (en) | 1984-12-27 | 1987-08-11 | Toyo Soda Manufacturing Co., Ltd. | Packing material for liquid chromatography and method for the preparation thereof |
| EP1179732B1 (en) | 2000-08-11 | 2004-03-17 | Rohm And Haas Company | Polymeric adsorbent and method of preparation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251996B1 (en) * | 1998-12-09 | 2001-06-26 | The Dow Chemical Company | Gel-type copolymer bead and ion-exchange resins made therefrom |
| DK1501369T3 (en) * | 2002-04-26 | 2015-09-28 | Genentech Inc | Non-affinity purification of proteins |
| DE602004026343D1 (en) * | 2003-10-24 | 2010-05-12 | Amgen Inc | PROCESS FOR PURIFYING PROTEINS IN A FLOW FRACTION FROM CHROMATOGRAPHY WITH HYDROPHOBIC INTERACTIONS |
| CN1927899A (en) * | 2006-09-01 | 2007-03-14 | 烟台硕德新材料有限公司 | Preparation method of micron-sized monodisperse copolymerized microspheres |
| AU2011214361C1 (en) * | 2010-02-12 | 2016-01-14 | Dpx Holdings B.V. | Single unit antibody purification |
| JP6292718B2 (en) | 2011-07-01 | 2018-03-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Method for separating monomeric polypeptides from aggregated polypeptides |
| US9096648B2 (en) * | 2011-08-19 | 2015-08-04 | Emd Millipore Corporation | Methods of reducing level of one or more impurities in a sample during protein purification |
| DK2970378T3 (en) * | 2013-03-15 | 2021-08-23 | Biogen Ma Inc | HYDROPHOB INTERACTION PROTEIN CHROMATOGRAPHY UNDER SALT-FREE CONDITIONS |
| US8946395B1 (en) * | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| CN107001411B (en) * | 2014-12-15 | 2021-07-23 | 默克专利股份公司 | Capture target molecules from crude solution |
-
2015
- 2015-02-18 DK DK15706374.4T patent/DK3114455T3/en active
- 2015-02-18 EP EP15706374.4A patent/EP3114455B1/en active Active
- 2015-02-18 SG SG11201607341SA patent/SG11201607341SA/en unknown
- 2015-02-18 CN CN201580011575.6A patent/CN106103477B/en active Active
- 2015-02-18 WO PCT/EP2015/000361 patent/WO2015131978A1/en not_active Ceased
- 2015-02-18 JP JP2016555750A patent/JP7037275B2/en active Active
- 2015-02-18 US US15/123,110 patent/US10457720B2/en active Active
- 2015-02-18 CA CA2942134A patent/CA2942134C/en active Active
- 2015-02-18 KR KR1020167027436A patent/KR102405382B1/en active Active
- 2015-02-18 ES ES15706374T patent/ES2784638T3/en active Active
- 2015-02-18 SG SG10201807572PA patent/SG10201807572PA/en unknown
-
2020
- 2020-03-23 JP JP2020050723A patent/JP7153041B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4382124A (en) | 1958-07-18 | 1983-05-03 | Rohm And Haas Company | Process for preparing macroreticular resins, copolymers and products of said process |
| US4382124B1 (en) | 1958-07-18 | 1994-10-04 | Rohm & Haas | Process for preparing macroreticular resins, copolymers and products of said process |
| JPS5798504A (en) | 1980-12-11 | 1982-06-18 | Mitsubishi Monsanto Chem Co | Production of vinyl polymer |
| US4686269A (en) | 1984-12-27 | 1987-08-11 | Toyo Soda Manufacturing Co., Ltd. | Packing material for liquid chromatography and method for the preparation thereof |
| JPS61141704A (en) | 1985-11-11 | 1986-06-28 | Mitsubishi Kasei Vinyl Co | Production of vinyl polymer |
| EP1179732B1 (en) | 2000-08-11 | 2004-03-17 | Rohm And Haas Company | Polymeric adsorbent and method of preparation |
Non-Patent Citations (7)
| Title |
|---|
| A. JUNGBAUER; G. CARTA: "Protein Chromatography, Process Development and Scale-Up", 2010, WILEY-VCH VERLAG |
| HAIYING CHEN ET AL: "Monoclonal Antibody and Antibody Drug Conjugate Separation by Polymer Based Reversed Phase Chromatography", PEGS 2014, PROTEIN AND ANTIBODY ENGINEERING SUMMIT | BOSTON, MA, USA, 5 May 2014 (2014-05-05) - 9 September 2014 (2014-09-09), PEGS2014, XP055184437 * |
| HUI F. LIU ET AL: "Recovery and purification process development for monoclonal antibody production", MABS, vol. 2, no. 5, 1 September 2010 (2010-09-01), pages 480 - 499, XP055027612, ISSN: 1942-0862, DOI: 10.4161/mabs.2.5.12645 * |
| I. C. EDMUNDSON: "Advances in Pharmaceutical Sciences", vol. 2, 1967, ACADEMIC PRESS, article "Particle-size analysis", pages: 95 - 174 |
| J KEVIN ET AL: "Purification of monoclonal antibodies using new pore size optimized HIC resins", BIOPROCESS INTERNATIONAL SHOW & EXHIBITION 2006, 6 November 2006 (2006-11-06), pages 1 - 18, XP055184385 * |
| SANCHAYITA GHOSE ET AL: "Purification of monoclonal antibodies by hydrophobic interaction chromatography under no-salt conditions", MABS, vol. 5, no. 5, 1 September 2013 (2013-09-01), pages 795 - 800, XP055131308, ISSN: 1942-0862, DOI: 10.4161/mabs.25552 * |
| SPACK E G ET AL: "Hydrophobic adsorption chromatography to reduce nonspecific staining by rhodamine-labeled antibodies", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS INC, NEW YORK, vol. 158, no. 1, 1 October 1986 (1986-10-01), pages 233 - 237, XP024818573, ISSN: 0003-2697, [retrieved on 19861001], DOI: 10.1016/0003-2697(86)90614-7 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016096071A1 (en) * | 2014-12-15 | 2016-06-23 | Merck Patent Gmbh | Target molecule capture from crude solutions |
| US10617975B2 (en) | 2014-12-15 | 2020-04-14 | Merck Patent Gmbh | Target molecule capture from crude solutions |
| US12139526B2 (en) | 2015-12-03 | 2024-11-12 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| US11186858B1 (en) | 2016-03-15 | 2021-11-30 | Fresenius Kabi Deutschland Gmbh | Methods for increasing biosimilarity |
| CN109715648A (en) * | 2016-09-15 | 2019-05-03 | 克拉维格两合股份有限公司 | Polymeric mesh object is used for the purposes of macromolecule purifying |
| WO2023007445A1 (en) * | 2021-07-29 | 2023-02-02 | Csl Behring Ag | Method of purifying immunoglobulin g and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102405382B1 (en) | 2022-06-03 |
| US20170073394A1 (en) | 2017-03-16 |
| JP7037275B2 (en) | 2022-03-16 |
| KR20160128411A (en) | 2016-11-07 |
| SG11201607341SA (en) | 2016-10-28 |
| US10457720B2 (en) | 2019-10-29 |
| ES2784638T3 (en) | 2020-09-29 |
| JP2020128373A (en) | 2020-08-27 |
| EP3114455A1 (en) | 2017-01-11 |
| CN106103477A (en) | 2016-11-09 |
| CA2942134A1 (en) | 2015-09-11 |
| DK3114455T3 (en) | 2020-04-06 |
| JP7153041B2 (en) | 2022-10-13 |
| CA2942134C (en) | 2023-08-15 |
| JP2017509621A (en) | 2017-04-06 |
| CN106103477B (en) | 2021-08-17 |
| EP3114455B1 (en) | 2020-01-15 |
| SG10201807572PA (en) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7153041B2 (en) | Robust antibody purification | |
| JP5032324B2 (en) | Composite filtration article | |
| CA2921883C (en) | Novel adsorbent composition and use thereof | |
| Yu et al. | Improving stability of virus-like particles by ion-exchange chromatographic supports with large pore size: advantages of gigaporous media beyond enhanced binding capacity | |
| JP6665184B2 (en) | Mixed bed ion exchange adsorbent | |
| van Beijeren et al. | Ion exchange membrane adsorption of bovine serum albumin—Impact of operating and buffer conditions on breakthrough curves | |
| Baran et al. | Efficient adsorption of hemoglobin from aqueous solutions by hybrid monolithic cryogel column | |
| JP7584481B2 (en) | Composite Materials for Bioseparation | |
| US10617975B2 (en) | Target molecule capture from crude solutions | |
| Wang et al. | Cored anion-exchange chromatography media for antibody flow-through purification | |
| Li et al. | High-speed chromatographic purification of plasmid DNA with a customized biporous hydrophobic adsorbent | |
| JP2003514655A (en) | Method for selectively removing a substance derived from a sample containing a compound having a nucleic acid structure | |
| JP2025509735A (en) | Methods and compositions for purifying small extracellular vesicles | |
| JP7344232B2 (en) | Composite materials for bioseparation | |
| KR20260046476A (en) | Method for purifying plasmid DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15706374 Country of ref document: EP Kind code of ref document: A1 |
|
| REEP | Request for entry into the european phase |
Ref document number: 2015706374 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2015706374 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 15123110 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: 2942134 Country of ref document: CA |
|
| ENP | Entry into the national phase |
Ref document number: 2016555750 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 20167027436 Country of ref document: KR Kind code of ref document: A |








